IELSG32

IELSG32Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary CNS lymphoma
Participants required:227 (enrolment completed)
Investigator responsible(s):A. Ferreri, G. Illerhaus
Objective(s):The primary objective of the first randomization is to establish the activity of three different chemotherapy combinations with high-dose methotrexate (HD-MTX) + high-dose cytarabine (HD-araC), HD-MTX + HDaraC + rituximab and HD-MTX + HD-araC + rituximab + thiotepa in patients with newly diagnosed PCNSL. At second randomization is to establish the efficacy of two consolidation strategies: conventional whole brain radiotherapy (WBRT) vs. high-dose chemotherapy supported by autologous stem cell transplantation (HDC + ASCT) in patients with newly diagnosed PCNSL.

Home | Go to Studies

Top